AdaptHealth (NASDAQ: AHCO) just got thumbs-up from Wall Street Zen. Upgraded from “hold” to “buy,” per Sunday report. Analysts seem optimistic .
Other financial voices have weighed in. February 26,Leerink Partners cut price target from $13.00 to $12.00,but maintained “outperform” rating. On other side,Royal Bank of Canada raised target from $13.00 to $15.00,stuck with “outperform” May 11. Jefferies Financial Group kept “hold” rating,target $11.00 April 20,while Truist Financial increased target from $13.00 to $14.00,calling it a “buy.”
Overall,five analysts recommend “buy,” two say “hold,” one says “sell.” Average rating: “Moderate Buy.” Price target averages $14.29,MarketBeat.com notes.
Friday, AdaptHealth shares opened at $10.16 . Stock's ranged from $8.06 low to $13.43 high past year . Market cap sits around $1.38 billion,with price-to-earnings ratio of -16.39, beta of 1.47.
Financials are mixed. Latest earnings May 5 showed EPS of ($0.12), missing consensus of $0.01 by $0.13. Revenue hit $819.80 million,beating estimates of $796.63 million, up 5.4% from last year.
Insider trades drew attention. Major shareholder Richard M. Cashin,Jr. bought 447,100 shares March 20 at $9.91 each,totaling ~$4.43 million. Increased his stake by 2.82%. Meanwhile,insider Russell E . Schuster III sold 11,275 shares June 1 at $10.06,netting $113,426.50. Now holds 136,538 shares.
Institutions hold large chunk of AdaptHealth, with 82.67% held by hedge funds,others. Recent moves: MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased stake by 4.4% first quarter, holding 60,495 shares worth $656,000. Goldman Sachs Group Inc . boosted stake by 32.4%,adding 139,828 shares,totaling 571,232 shares valued at $6.19 million.
AdaptHealth,big U.S. player in home medical equipment,services. Focus on respiratory care,mobility solutions,bathroom safety . Aim to improve life quality for chronic,acute patients…
